NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 107 versions: 13 with changes below, 37 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 44 → 49 locations
- Site contacts updated at 3 of 49 sites
- Minor Study sites: 46 to 49
- Minor Study sites: 45 to 46
- Interventions modified
- Secondary endpoints: details revised at 1 of 20 entries
- Minor Interventions: Biospecimen Collection (Procedure), Device Usage (Device), Electronic Health Record Review (Other), Multi-Cancer Detection Test… to Biospecimen Collection (Procedure), Device Usage (Device), Electronic Health Record Review (Other), Multi-Cancer Early Detection Test…
- Secondary endpoints: details revised at 2 of 20 entries
- Site contacts updated at 1 of 45 sites
- Minor Study sites: 44 to 45
- Notable Eligibility criteria expanded, about 11 words
- Secondary endpoints: details revised at 4 of 20 entries
- Site details revised at 2 of 44 sites
- Publications: details revised at 1 of 1 entry
- Minor Trial sites expanded: 41 → 44 locationsv101
- Minor Study sites: 40 to 41v100
- Notable Eligibility criteria expanded, about 46 words
- Study sites: 39 to 40
- Minor Study sites: 38 to 39v97
- Minor Study sites: 37 to 38v96
- Notable Primary completion pushed from Dec 31, 2027 to Jan 31, 2029
- Start date: Jun 16, 2025 to Jun 18, 2025
- Study description expanded, about 64 words
- Minor Study sites: 36 to 37v91
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (20)
Show 15 moreShow less
Arms and interventions
Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
Participants undergo blood collection at enrollment and after one year on study.
Procedures: Biospecimen Collection, Multi-Cancer Early Detection Test
Devices: Device Usage
Other: Electronic Health Record Review, Questionnaire Administration
Sites
49 sites in 1 country